Ferric carboxymaltose versus ferric gluconate in hemodialysis patients: reduction of erythropoietin dose in 4 years of follow-up
Background: Ferric carboxymaltose (FCM) is a parenteral, dextran-free iron formulation designed to overcome the limitations of existing iron preparations. The main aim of this study was to retrospectively examine results obtained from a long period of FCM therapy in hemodialysis patients who have be...
Gespeichert in:
Veröffentlicht in: | Kidney research and clinical practice 2020-09, Vol.39 (3), p.334 |
---|---|
Hauptverfasser: | , , , , , , , |
Format: | Artikel |
Sprache: | kor |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | |
---|---|
container_issue | 3 |
container_start_page | 334 |
container_title | Kidney research and clinical practice |
container_volume | 39 |
creator | Antonio Lacquaniti Patrizio Pasqualetti Teresa Casuscelli Di Tocco Susanna Campo Stefania Rovito Maurizio Bucca Antonino Ragusa Paolo Monardo |
description | Background: Ferric carboxymaltose (FCM) is a parenteral, dextran-free iron formulation designed to overcome the limitations of existing iron preparations. The main aim of this study was to retrospectively examine results obtained from a long period of FCM therapy in hemodialysis patients who have been previously treated with ferric gluconate (FX). Markers of iron metabolism, erythropoietin (EPO) doses, and effects on anemic status have been analysed.
Methods: The study was performed with a follow up period of 4 years, when patients were treated before with FX and then switched to FCM. A total of 25 patients were included in the study.
Results: FCM increased transferrin saturation (TSAT) levels by 11.9% (P < 0.001) with respect to FX. Events of TSAT less than 20% were reduced during FCM. The monthly dose of EPO was reduced in the FCM period (-6,404.1 international unit [IU]; 95% confidence interval, -10,643.5 IU; -2,164.6 IU; P = 0.003), as well as the erythropoietin resistance index (P = 0.004). During the period with FCM, ferritin levels were higher than during FX (P < 0.001), while transferrin was reduced (P = 0.001).
Conclusion: During FCM treatment, minor doses of EPO were administered if compared to those delivered during FX therapy. Stable and on target levels of hemoglobin were maintained with better control of anemia through high levels of ferritin and TSAT. |
format | Article |
fullrecord | <record><control><sourceid>kiss</sourceid><recordid>TN_cdi_kiss_primary_3827335</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><kiss_id>3827335</kiss_id><sourcerecordid>3827335</sourcerecordid><originalsourceid>FETCH-kiss_primary_38273353</originalsourceid><addsrcrecordid>eNp9jDFug0AQRbdwpCCHE6SZCyAZ1gSS1jLKAdJbaxjMKAuDZhbb2-XoseXUqV7x_vsrkxRFnmfvuS2eTapKx025qez2ra4T89OgCLXQOjnyNY7OB1aEM4ouCv1DnvzS8uQCAk0w4MgdOR-VFGYXCKegHyDYLW0gnoB7QIlhEJ6ZMNyS7n554xYiOtH7omfv-ZIt84t56p1XTP-4Nq_N_mv3mX2T6mEWGp3Eg62LytrS_m9_ASlXTJM</addsrcrecordid><sourcetype>Publisher</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Ferric carboxymaltose versus ferric gluconate in hemodialysis patients: reduction of erythropoietin dose in 4 years of follow-up</title><source>DOAJ Directory of Open Access Journals</source><source>PubMed Central Open Access</source><source>PubMed Central</source><creator>Antonio Lacquaniti ; Patrizio Pasqualetti ; Teresa Casuscelli Di Tocco ; Susanna Campo ; Stefania Rovito ; Maurizio Bucca ; Antonino Ragusa ; Paolo Monardo</creator><creatorcontrib>Antonio Lacquaniti ; Patrizio Pasqualetti ; Teresa Casuscelli Di Tocco ; Susanna Campo ; Stefania Rovito ; Maurizio Bucca ; Antonino Ragusa ; Paolo Monardo</creatorcontrib><description>Background: Ferric carboxymaltose (FCM) is a parenteral, dextran-free iron formulation designed to overcome the limitations of existing iron preparations. The main aim of this study was to retrospectively examine results obtained from a long period of FCM therapy in hemodialysis patients who have been previously treated with ferric gluconate (FX). Markers of iron metabolism, erythropoietin (EPO) doses, and effects on anemic status have been analysed.
Methods: The study was performed with a follow up period of 4 years, when patients were treated before with FX and then switched to FCM. A total of 25 patients were included in the study.
Results: FCM increased transferrin saturation (TSAT) levels by 11.9% (P < 0.001) with respect to FX. Events of TSAT less than 20% were reduced during FCM. The monthly dose of EPO was reduced in the FCM period (-6,404.1 international unit [IU]; 95% confidence interval, -10,643.5 IU; -2,164.6 IU; P = 0.003), as well as the erythropoietin resistance index (P = 0.004). During the period with FCM, ferritin levels were higher than during FX (P < 0.001), while transferrin was reduced (P = 0.001).
Conclusion: During FCM treatment, minor doses of EPO were administered if compared to those delivered during FX therapy. Stable and on target levels of hemoglobin were maintained with better control of anemia through high levels of ferritin and TSAT.</description><identifier>ISSN: 2211-9132</identifier><language>kor</language><publisher>대한신장학회</publisher><subject>Anemia ; Erythropoietin resistance index ; Ferric carboxymaltose ; Hemodialysis</subject><ispartof>Kidney research and clinical practice, 2020-09, Vol.39 (3), p.334</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,782,786</link.rule.ids></links><search><creatorcontrib>Antonio Lacquaniti</creatorcontrib><creatorcontrib>Patrizio Pasqualetti</creatorcontrib><creatorcontrib>Teresa Casuscelli Di Tocco</creatorcontrib><creatorcontrib>Susanna Campo</creatorcontrib><creatorcontrib>Stefania Rovito</creatorcontrib><creatorcontrib>Maurizio Bucca</creatorcontrib><creatorcontrib>Antonino Ragusa</creatorcontrib><creatorcontrib>Paolo Monardo</creatorcontrib><title>Ferric carboxymaltose versus ferric gluconate in hemodialysis patients: reduction of erythropoietin dose in 4 years of follow-up</title><title>Kidney research and clinical practice</title><addtitle>Kidney Research and Clinical Practice(구 대한신장학회지)</addtitle><description>Background: Ferric carboxymaltose (FCM) is a parenteral, dextran-free iron formulation designed to overcome the limitations of existing iron preparations. The main aim of this study was to retrospectively examine results obtained from a long period of FCM therapy in hemodialysis patients who have been previously treated with ferric gluconate (FX). Markers of iron metabolism, erythropoietin (EPO) doses, and effects on anemic status have been analysed.
Methods: The study was performed with a follow up period of 4 years, when patients were treated before with FX and then switched to FCM. A total of 25 patients were included in the study.
Results: FCM increased transferrin saturation (TSAT) levels by 11.9% (P < 0.001) with respect to FX. Events of TSAT less than 20% were reduced during FCM. The monthly dose of EPO was reduced in the FCM period (-6,404.1 international unit [IU]; 95% confidence interval, -10,643.5 IU; -2,164.6 IU; P = 0.003), as well as the erythropoietin resistance index (P = 0.004). During the period with FCM, ferritin levels were higher than during FX (P < 0.001), while transferrin was reduced (P = 0.001).
Conclusion: During FCM treatment, minor doses of EPO were administered if compared to those delivered during FX therapy. Stable and on target levels of hemoglobin were maintained with better control of anemia through high levels of ferritin and TSAT.</description><subject>Anemia</subject><subject>Erythropoietin resistance index</subject><subject>Ferric carboxymaltose</subject><subject>Hemodialysis</subject><issn>2211-9132</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNp9jDFug0AQRbdwpCCHE6SZCyAZ1gSS1jLKAdJbaxjMKAuDZhbb2-XoseXUqV7x_vsrkxRFnmfvuS2eTapKx025qez2ra4T89OgCLXQOjnyNY7OB1aEM4ouCv1DnvzS8uQCAk0w4MgdOR-VFGYXCKegHyDYLW0gnoB7QIlhEJ6ZMNyS7n554xYiOtH7omfv-ZIt84t56p1XTP-4Nq_N_mv3mX2T6mEWGp3Eg62LytrS_m9_ASlXTJM</recordid><startdate>20200930</startdate><enddate>20200930</enddate><creator>Antonio Lacquaniti</creator><creator>Patrizio Pasqualetti</creator><creator>Teresa Casuscelli Di Tocco</creator><creator>Susanna Campo</creator><creator>Stefania Rovito</creator><creator>Maurizio Bucca</creator><creator>Antonino Ragusa</creator><creator>Paolo Monardo</creator><general>대한신장학회</general><scope>HZB</scope><scope>Q5X</scope></search><sort><creationdate>20200930</creationdate><title>Ferric carboxymaltose versus ferric gluconate in hemodialysis patients: reduction of erythropoietin dose in 4 years of follow-up</title><author>Antonio Lacquaniti ; Patrizio Pasqualetti ; Teresa Casuscelli Di Tocco ; Susanna Campo ; Stefania Rovito ; Maurizio Bucca ; Antonino Ragusa ; Paolo Monardo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-kiss_primary_38273353</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>kor</language><creationdate>2020</creationdate><topic>Anemia</topic><topic>Erythropoietin resistance index</topic><topic>Ferric carboxymaltose</topic><topic>Hemodialysis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Antonio Lacquaniti</creatorcontrib><creatorcontrib>Patrizio Pasqualetti</creatorcontrib><creatorcontrib>Teresa Casuscelli Di Tocco</creatorcontrib><creatorcontrib>Susanna Campo</creatorcontrib><creatorcontrib>Stefania Rovito</creatorcontrib><creatorcontrib>Maurizio Bucca</creatorcontrib><creatorcontrib>Antonino Ragusa</creatorcontrib><creatorcontrib>Paolo Monardo</creatorcontrib><collection>Korean Studies Information Service System (KISS)</collection><collection>Korean Studies Information Service System (KISS) B-Type</collection><jtitle>Kidney research and clinical practice</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Antonio Lacquaniti</au><au>Patrizio Pasqualetti</au><au>Teresa Casuscelli Di Tocco</au><au>Susanna Campo</au><au>Stefania Rovito</au><au>Maurizio Bucca</au><au>Antonino Ragusa</au><au>Paolo Monardo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Ferric carboxymaltose versus ferric gluconate in hemodialysis patients: reduction of erythropoietin dose in 4 years of follow-up</atitle><jtitle>Kidney research and clinical practice</jtitle><addtitle>Kidney Research and Clinical Practice(구 대한신장학회지)</addtitle><date>2020-09-30</date><risdate>2020</risdate><volume>39</volume><issue>3</issue><spage>334</spage><pages>334-</pages><issn>2211-9132</issn><abstract>Background: Ferric carboxymaltose (FCM) is a parenteral, dextran-free iron formulation designed to overcome the limitations of existing iron preparations. The main aim of this study was to retrospectively examine results obtained from a long period of FCM therapy in hemodialysis patients who have been previously treated with ferric gluconate (FX). Markers of iron metabolism, erythropoietin (EPO) doses, and effects on anemic status have been analysed.
Methods: The study was performed with a follow up period of 4 years, when patients were treated before with FX and then switched to FCM. A total of 25 patients were included in the study.
Results: FCM increased transferrin saturation (TSAT) levels by 11.9% (P < 0.001) with respect to FX. Events of TSAT less than 20% were reduced during FCM. The monthly dose of EPO was reduced in the FCM period (-6,404.1 international unit [IU]; 95% confidence interval, -10,643.5 IU; -2,164.6 IU; P = 0.003), as well as the erythropoietin resistance index (P = 0.004). During the period with FCM, ferritin levels were higher than during FX (P < 0.001), while transferrin was reduced (P = 0.001).
Conclusion: During FCM treatment, minor doses of EPO were administered if compared to those delivered during FX therapy. Stable and on target levels of hemoglobin were maintained with better control of anemia through high levels of ferritin and TSAT.</abstract><pub>대한신장학회</pub><tpages>10</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 2211-9132 |
ispartof | Kidney research and clinical practice, 2020-09, Vol.39 (3), p.334 |
issn | 2211-9132 |
language | kor |
recordid | cdi_kiss_primary_3827335 |
source | DOAJ Directory of Open Access Journals; PubMed Central Open Access; PubMed Central |
subjects | Anemia Erythropoietin resistance index Ferric carboxymaltose Hemodialysis |
title | Ferric carboxymaltose versus ferric gluconate in hemodialysis patients: reduction of erythropoietin dose in 4 years of follow-up |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-04T11%3A24%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-kiss&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Ferric%20carboxymaltose%20versus%20ferric%20gluconate%20in%20hemodialysis%20patients:%20reduction%20of%20erythropoietin%20dose%20in%204%20years%20of%20follow-up&rft.jtitle=Kidney%20research%20and%20clinical%20practice&rft.au=Antonio%20Lacquaniti&rft.date=2020-09-30&rft.volume=39&rft.issue=3&rft.spage=334&rft.pages=334-&rft.issn=2211-9132&rft_id=info:doi/&rft_dat=%3Ckiss%3E3827335%3C/kiss%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rft_kiss_id=3827335&rfr_iscdi=true |